Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $28.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 182.54% to $28.3 million in Q1 2023 year-over-year; TTM through Dec 2023 was $28.3 million, a 43.42% increase, with the full-year FY2023 number at $28.3 million, up 43.42% from a year prior.
  • Change in Acquisitions & Divestments was $28.3 million for Q1 2023 at Cartesian Therapeutics, up from $5.7 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $28.3 million in Q1 2023 to a low of $2.0 million in Q1 2019.
  • A 4-year average of $10.1 million and a median of $8.2 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 65.53% in 2019, then surged 182.54% in 2023.
  • Cartesian Therapeutics' Change in Acquisitions & Divestments stood at $14.4 million in 2019, then tumbled by 30.35% to $10.0 million in 2021, then tumbled by 43.0% to $5.7 million in 2022, then skyrocketed by 395.68% to $28.3 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Change in Acquisitions & Divestments are $28.3 million (Q1 2023), $5.7 million (Q4 2022), and $4.0 million (Q3 2022).